Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,157,809 shares of the biotechnology company’s stock after selling 5,115 shares during the quarter. Geode Capital Management LLC’s holdings in Exelixis were worth $171,806,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EXEL. Norges Bank bought a new position in shares of Exelixis in the fourth quarter valued at approximately $94,867,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after buying an additional 1,613,482 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Globeflex Capital L P grew its holdings in Exelixis by 203.8% during the fourth quarter. Globeflex Capital L P now owns 975,151 shares of the biotechnology company’s stock worth $32,473,000 after acquiring an additional 654,200 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Exelixis in the 4th quarter worth approximately $17,046,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EXEL shares. Brookline Capital Management initiated coverage on Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating on the stock. UBS Group upped their price target on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Truist Financial raised their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Piper Sandler increased their price objective on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Stock Down 5.8 %

NASDAQ:EXEL opened at $34.57 on Monday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The stock’s 50 day moving average price is $35.90 and its two-hundred day moving average price is $33.65.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity

In other news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.